Summary:
- The article explores the systemic influence of the pharmaceutical industry on medical education, clinical research, and the practice of medicine.
- It examines the "capture" of regulatory bodies and academic institutions by corporate interests, arguing that this creates a bias that prioritizes profit over evidence-based patient outcomes.
- The author critiques how financial incentives shape the definition of "standard of care," suggesting a need for increased transparency and independence in medical science.